These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 18600572)

  • 1. From virtuality to reality - Virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective.
    Rester U
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):559-68. PubMed ID: 18600572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The devil is still in the details--driving early drug discovery forward with biophysical experimental methods.
    Lundqvist T
    Curr Opin Drug Discov Devel; 2005 Jul; 8(4):513-9. PubMed ID: 16022188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using X-ray crystallography in drug discovery.
    Rowland RS
    Curr Opin Drug Discov Devel; 2002 Jul; 5(4):613-9. PubMed ID: 12197319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystallography, NMR and virtual screening: integrated tools for drug discovery.
    Muchmore SW; Hajduk PJ
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):544-9. PubMed ID: 12951817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designer drugs: the evolving science of drug discovery.
    Wanke LA; DuBose RF
    Pharm Pract Manag Q; 1998 Jul; 18(2):13-22. PubMed ID: 10185235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lead optimization via high-throughput molecular docking.
    Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
    Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virtual screening - what does it give us?
    Köppen H
    Curr Opin Drug Discov Devel; 2009 May; 12(3):397-407. PubMed ID: 19396741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virtual screening in lead discovery and optimization.
    Jain AN
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):396-403. PubMed ID: 15338948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel 2D fingerprints for ligand-based virtual screening.
    Ewing T; Baber JC; Feher M
    J Chem Inf Model; 2006; 46(6):2423-31. PubMed ID: 17125184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating medicinal chemistry, organic/combinatorial chemistry, and computational chemistry for the discovery of selective estrogen receptor modulators with Forecaster, a novel platform for drug discovery.
    Therrien E; Englebienne P; Arrowsmith AG; Mendoza-Sanchez R; Corbeil CR; Weill N; Campagna-Slater V; Moitessier N
    J Chem Inf Model; 2012 Jan; 52(1):210-24. PubMed ID: 22133077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical feature-based pharmacophores and virtual library screening for discovery of new leads.
    Langer T; Krovat EM
    Curr Opin Drug Discov Devel; 2003 May; 6(3):370-6. PubMed ID: 12833670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies and tactics for optimizing the Hit-to-Lead process and beyond--a computational chemistry perspective.
    Manly CJ; Chandrasekhar J; Ochterski JW; Hammer JD; Warfield BB
    Drug Discov Today; 2008 Feb; 13(3-4):99-109. PubMed ID: 18275907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Affinity-based screening techniques for enhancing lead discovery.
    Comess KM; Schurdak ME
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):411-6. PubMed ID: 15338950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CLEVER: pipeline for designing in silico chemical libraries.
    Song CM; Bernardo PH; Chai CL; Tong JC
    J Mol Graph Model; 2009 Jan; 27(5):578-83. PubMed ID: 18986817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating molecular design resources within modern drug discovery research: the Roche experience.
    Stahl M; Guba W; Kansy M
    Drug Discov Today; 2006 Apr; 11(7-8):326-33. PubMed ID: 16580974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-throughput X-ray crystallography for drug discovery.
    Blundell TL; Patel S
    Curr Opin Pharmacol; 2004 Oct; 4(5):490-6. PubMed ID: 15351354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docking and scoring in virtual screening for drug discovery: methods and applications.
    Kitchen DB; Decornez H; Furr JR; Bajorath J
    Nat Rev Drug Discov; 2004 Nov; 3(11):935-49. PubMed ID: 15520816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of virtual and high-throughput screening.
    Bajorath J
    Nat Rev Drug Discov; 2002 Nov; 1(11):882-94. PubMed ID: 12415248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of protein-ligand interaction fingerprints in docking.
    Brewerton SC
    Curr Opin Drug Discov Devel; 2008 May; 11(3):356-64. PubMed ID: 18428089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.